Wed, March 30, 2022
Tue, March 29, 2022
Mon, March 28, 2022

Judah Frommer Maintained (ABOS) at Buy with Decreased Target to $17 on, Mar 29th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-17-on-mar-29th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Judah Frommer of Credit Suisse, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Buy with Decreased Target from $26 to $17 on, Mar 29th, 2022.

Judah has made no other calls on ABOS in the last 4 months.



There is 1 other peer that has a rating on ABOS. Out of the 1 peers that are also analyzing ABOS, 0 agree with Judah's Rating of Hold.



This is the rating of the analyst that currently disagrees with Judah


  • Geoff Meacham of "B of A Securities" Upgraded from Hold to Strong Buy and Decreased Target to $14 on, Friday, January 21st, 2022